Drug intelligence / Profile preview

clofibride

Development stage: Phase 3
Lead developer: AkzoNobel
Modality: Small Molecules

Overview

Clofibride is a small molecule classified as a fibric acid derivative. It is structurally related to clofibrate and has been investigated for its lipid-lowering properties, particularly in the management of hyperlipidemia. The drug acts by modulating lipid metabolism, but detailed information on its mechanism of action, clinical efficacy, and safety profile remains limited in publicly available sources. Its use appears to be experimental or investigational rather than widely approved or marketed[10].

Brand names: ClofibridaClofibrideClofibridum
Other names: ClofibridaClofibrideClofibridum

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on clofibride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clofibride.

Explore the full profile